Drug Trial Radar · NCT06384547
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
May 23, 2024
Primary completion
May 1, 2025
Study completion Jan 19, 2026
Sponsor
- Lead sponsor
- Viridian Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with TED. The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in participants with TED.
Conditions
- Thyroid Eye Disease
Interventions
VeligrotugDrug
5 infusions of veligrotug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15Time frame: Baseline through Week 15
Locations
50 sites in 7 countries. Site status is shown where the registry gives one.
United Medical Research Institute
Inglewood, California
Advancing Research International, LLC
Los Angeles, California
Stanford Byers Eye Institute
Palo Alto, California
Cockerham Eye Consultants, PC
San Diego, California
FOMAT Medical Research
Santa Maria, California
University of Colorado - Dept of Ophthalmology
Aurora, Colorado
Sina Medical Center LLC
Homestead, Florida
Med-Care Research Inc.
Miami, Florida
Edward Jenner Research Group Center LLC
Plantation, Florida
Sarasota Retina Institute
Sarasota, Florida
Vision Medical Research Inc.
Orland Park, Illinois
University Health Diabetes, Endocrinology & Nephrology Center
Kansas City, Kansas
KU Medical Center, University of Kansas
Kansas City, Kansas
Massachusetts Eye and Ear
Boston, Massachusetts
Ophthalmic Consultants of Boston
Weymouth, Massachusetts
Fraser Eye Care Center
Fraser, Michigan
Kahana Oculoplastic & Orbital Surgery
Livonia, Michigan
University of Minnesota, Department of Ophthalmology and Visual Neurosciences
Minneapolis, Minnesota
Advancing Research International, LLC
Las Vegas, Nevada
Rutgers- New Jersey Medical School- Newark
Newark, New Jersey
New York Eye Ear Infirmary of Mount Sinai
New York, New York
Baylor College of Medicine (BCM) - Ophthalmology
Houston, Texas
Neuro-Eye Clinical Trials
Houston, Texas
Neuro-Ophthalmology of Texas, PLLC
Houston, Texas
University of Vermont Medical Center
Burlington, Vermont
West Virginia University Eye Institute
Morgantown, West Virginia
Sydney Eye Hospital
Sydney, Australia
North Shore Eye Surgery
Sydney, Australia
CHU d'Angers
Angers, France
Centre Hospitalier National D'ophtalmologie
Des Quinze Vingts Paris, France
CH Nice
Nice, France
AP-HP - Hôpital de la Pitié Salpétrière
Paris, France
Universitätsmedizin Göttingen
Göttingen, Germany
Johannes Gutenberg-University Medical Center
Mainz, Germany
NZOZ E-Vita
Bialystok, Poland
Specjalistyczny Osrodek Okulistyczny Oculomedica
Bydgoszcz, Poland
Santa Familia PTG Lodz
Lódz, Poland
Panstwowy Instytut Medyczny MSWiA
Warsaw, Poland
4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ
Wroclaw, Poland
Clinica Bonanova de Cirugia Ocular
Barcelona, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.